Victorian RNA researchers have partnered with a U.S based biotech firm, InterVenn, to help develop new therapeutics for cancer detection.

Victorian Minister for Innovation, Medical Research and the Digital Economy Jaala Pulford announced today that Intervenn Biosciences will be establishing a commercial and research lab at St Vincent Hospital in Melbourne.

“InterVenn is at the cutting edge of biotechnologies and their establishment in Melbourne will provide access to the latest in cancer detection technologies,” she said.

With the partnership of mRNA Victoria, Intervenn hopes that their AI Biotech will help detect cancer and find out how a patient will respond to their treatments.

InterVenn CEO Erwin Estigarribia said it will bring AI-powered software to researchers and physicians in Melbourne.

“Australia is a strategic geography with a very rich talent pool and potential for collaborations to help our
mission where we continue to build a world where no patient is blind sighted by disease,” she said.

The non-invasive precision medicine is anticipated to find new treatments for ovarian, pancreatic, liver, prostate, and kidney cancer.

The Andrews Labour Government have invested $500 million into advanced medical research techniques, including a $50 million commitment to the mRNA, and $400 million invested into the recently established Australian Institute for Infectious Disease (AIID).

Pulford is confident that Intervenn’s presence in Melbourne will provide more employment opportunities.

“This partnership will create local jobs and bolster Victoria’s reputation internationally as a location for innovative biotech research and development,” she said.

Photo: Chelsea FC by Simon Reza available HERE and used under a Creative Commons licence. The photo has not been modified.